Orchestra BioMed Holdings (OBIO) Total Liabilities (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Total Liabilities for 7 consecutive years, with $49.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities rose 17.77% year-over-year to $49.7 million; the TTM figure through Mar 2026 stood at $49.7 million (up 17.77% YoY), while the FY2025 annual figure was $51.5 million, up 19.12% from the prior year.
• Total Liabilities eased to $49.7 million in Q1 2026 per OBIO's latest filing, from $51.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $61.1 million in Q3 2025 and bottomed at $5.9 million in Q1 2022.
• Historically, Total Liabilities has averaged $33.7 million across 5 years, with a median of $36.5 million in 2023.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 646.47% — and 2023, when it plunged 36.87%.
• Orchestra BioMed Holdings' Total Liabilities stood at $43.0 million in 2022, then slumped by 36.87% to $27.2 million in 2023, then soared by 59.06% to $43.2 million in 2024, then rose by 19.12% to $51.5 million in 2025, then declined by 3.47% to $49.7 million in 2026.
• Business Quant data shows OBIO's Total Liabilities at $49.7 million in Q1 2026, $51.5 million in Q4 2025, and $61.1 million in Q3 2025.